依诺肝素与达肝素用于非介入治疗非ST段抬高型急性冠状动脉综合征患者的短期疗效和安全性对比  

Short-term efficacy and safety of enoxaparin and dalteparin for NSTE-ACS patients without percutaneous coronary intervention

作　　者：王寅[1] 蒋利[1] 

机构地区：[1]上海市长宁区中心医院心内科,上海200336

出　　处：《世界临床药物》2012年第1期30-33,36,共5页World Clinical Drug

摘　　要：目的观察比较依诺肝素和达肝素用于非介入治疗非ST段抬高型急性冠状动脉综合征(NSTE-ACS)患者的短期疗效和安全性。方法 406例NSTE-ACS住院患者,随机接受依诺肝素(n=204)或达肝素(n=202)治疗,治疗后第30天观察两组患者的短期心功能改善、心脏事件(包括心绞痛、急性心肌梗死再发和死亡)发生率及临床出血情况。结果两组短期心功能改善及心脏事件发生的差异无统计学意义(P>0.05),依诺肝素组轻度出血事件少于达肝素组(P<0.01),严重出血事件两组差异无统计学意义(P>0.05)。结论对于非介入治疗的NSTE-ACS患者,依诺肝素与达肝素短期疗效相当,但安全性更优。Objective To evaluation the short-term efficacy and safety of enoxaparin and dalteparin for non-ST-segment elevation acute coronary syndrome （NSTE-ACS） patients without percutaneous coronary intervention （PCI）. Methods In total of 406 inpatients suffered from NSTE-ACS were randomly divided into enoxaparin group （n=204） and dalteparin group （n=202）. The improvement of heart function, incidence of cardiac events （recurrent angina, recurrent myocardial infarction and death） and incidence of bleeding were observed at day 30 after treatment. Results There were no significant differences between two groups in the improvement of heart function and incidence of cardiac events （P〉0.05）. The incidence of minor bleeding in enoxaparin group was significant lower than that in dalteparin group （P〈0.01）. The incidence of major bleeding in two groups had no difference （P〉0.05）. Conclusion For the NSTE-ACS patients without PCI, the shortterm efficacy of enoxaparin is equal to that of dalteparin, but the safety of enoxaprin is superior to that of dalteparin.

关 键 词：急性冠状动脉综合征 非ST段抬高 低分子肝素 安全性 短期疗效 

分 类 号：R973.2[医药卫生—药品] R541.4[医药卫生—药学]